Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Efgartigimod PH20 SC in Idiopathic Inflammatory Myopathy
NCT05979441Phase 3Enrolling by invitation
- Sponsor
- argenx
- Start
- Sep 2023
- Primary completion
- Sep 2028
- Modality
- Antibody Fragments, Therapeutic Enzymes
- Countries
- 29
01
Overview
A Phase 3 trial of efgartigimod alfa + hyaluronidase-qvfc in idiopathic inflammatory myopathy (IIM), sponsored by argenx. Started Sep 2023; status: enrolling by invitation.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT05979441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979441.